Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.

Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.
J Dermatolog Treat. 2018 May 08;:1-25
Authors: Thomas LW, Lee EB, Wu JJ
Abstract
Three main biologics target the IL-17 pathway; these include secukinmab, ixekizumab, brodalumab, all of which are approved for treatment of moderate-to-severe plaque psoriasis. We performed a systematic review of the literature to determine if IL-17 inhibitors are prone to developing ADA and how efficacy of treatment is influenced. A total of 14 papers were reviewed. Only one secukinmab trial detected treatment-emergent ADA in 4 out of 996 (0.41%) patients during the 52-week treatment period. Two of these patients (1 on 150-mg retreatment as needed and 1 on 150-mg fixed interval) were found to have neutralizing antibodies, however they were not associated with decreased efficacy. One paper reported ADAs against ixekizumab. 103 out of 1150 (9%) developed titers to ixekizumab after receiving 160 mg loading dose followed by 80 mg every two weeks. 19 out of 1150 (1.7%) developed high titer (>1:1280) which impacted clinical outcomes. Three studies did detect ADA against brodalumab, however none of were neutralizing. It is difficult to draw a conclusion from our findings given the variability in ADA development. Most trials did not develop ADA, and if they did, the majority of the time they were not neutralizing. Only ixekizumab showed decreased efficacy but no increased advers...

Source: Journal of Dermatological Treatment - May 10, 2018 Category: Dermatology Tags: J Dermatolog Treat Source Type: research